Last reviewed · How we verify
Bexide (DIXANTHOGEN)
Bexide (generic name: DIXANTHOGEN) is a dixanthogen drug. It is currently in Phase 2 development.
Bexide works by interacting with a specific molecular target to produce a therapeutic effect.
Bexide, also known as a dixanthogen, is a small molecule drug with an unknown target. Its exact mechanism of action and approved indications are not publicly available. The commercial status of Bexide is also unclear, with no information on patent status or generic manufacturers. Further research is needed to understand the pharmacological properties and safety considerations of this compound. As a result, Bexide is not a well-characterized drug.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DIXANTHOGEN |
|---|---|
| Drug class | dixanthogen |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and Bexide is a key that fits into one of those locks. When it binds to the lock, it triggers a series of events that ultimately lead to a therapeutic effect. However, the exact lock that Bexide binds to and the events that follow are not yet fully understood.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bexide CI brief — competitive landscape report
- Bexide updates RSS · CI watch RSS
Frequently asked questions about Bexide
What is Bexide?
How does Bexide work?
What is the generic name of Bexide?
What drug class is Bexide in?
What development phase is Bexide in?
Related
- Drug class: All dixanthogen drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing